secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-06-24T21:14:45+00:00
Accession:  0001104659-26-077354
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium Therapeutics prices $805M public offering of 20.6M shares at $34 each, upsized from $700M
--------------------------------------------------------------------------------

- Offering of 20,588,236 common shares at $34.00 per share, with full exercise of underwriters' 30-day option for additional 3,088,235 shares.
- Gross proceeds ~$805M; net proceeds ~$758M after underwriting discounts and expenses.
- Proceeds to fund R&D, commercialization preparation for DT120 ODT if approved, and working capital.
- Underwriters: J.P. Morgan, Jefferies, Leerink, BofA, Evercore ISI, Stifel, Oppenheimer, LifeSci.
- Expected close June 25, 2026; 60-day lock-up for directors, officers, and company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/0001104659-26-077354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/tm2618395d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-077354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer